Abstract:Background/Objectives: A comprehensive comparison of intraoperative, oncological, and functional outcomes of RARP performed with different robotic surgical platforms is critically needed. Our aim is to compare the oncological and functional outcomes of RARP performed using the novel HugoTM RAS system with those from the daVinci system, the reference standard, at a high-volume robotic center, with an extended follow-up period (one year). Methods: We analyzed the data of 400 patients undergoing RARP ± pelvic lymph node dissection between 2021 and 2023, using propensity score (PS) matching to correct for treatment selection bias. All procedures were performed by three surgeons with HugoTM RAS or daVinci. This analysis extends the follow-up period to 1 year, focusing on specific functional and oncological outcomes, building on our previous 3-month evaluation of perioperative outcomes. The primary outcome was the trifecta rate, defined as freedom from biochemical recurrence, continence, and erectile function recovery. Secondary outcomes included detailed assessments of oncological outcomes (PSA levels) and functional outcomes (continence and erectile function). Results: The propensity score-matched cohort included 99 matched pairs (198 patients), balanced for all covariates. No significant differences were found in trifecta rates between the two platforms at 1-year follow-up (Hugo: 25.25%, daVinci: 27.27%, p = 0.743). Both groups showed improved trifecta rates when considering only nerve-sparing procedures (Hugo: 36.84%, daVinci: 35.59%, p = 0.889). Continence rates were similar (Hugo: 87.9%, daVinci: 89.9%, p = 0.327), as were the undetectable PSA rates (Hugo: 92.9%, daVinci: 88.8%, p = 0.158). Also, the erectile function recovery rate did not differ significantly between the groups. Conclusions: This is the first study comparing 1-year functional and oncological outcomes of RARP performed with HugoTM RAS and daVinci surgical robotic systems using PS matching. Functional and oncological outcomes of RARP were comparable between the two robotic platforms. These findings confirm that the transition to the HugoTM platform does not compromise surgical proficiency or patient outcomes, even if further long-term studies are necessary to confirm these results.

Outcomes of robotic surgery for inflammatory bowel disease using the Medtronic HugoTM Robotic-Assisted Surgical platform: a single center experience

Outcomes of robotic surgery for inflammatory bowel disease using the Medtronic Hugo™ Robotic-Assisted Surgical platform: a single center experience

Utility guideline and considerations for the novel Hugo™ RAS (robotic-assisted surgery) system in colorectal surgery: surgical outcomes and initial experience in a tertiary center

Initial experience of robotically assisted endometriosis surgery with a novel robotic system: first case series in a tertiary care center

Propensity Score-Matched Comparative Analysis

Minimally Invasive Surgery for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Robotic Versus Laparoscopic Surgical Techniques

Utility guideline and considerations for the novel HugoTM RAS (robotic-assisted surgery) system in colorectal surgery: surgical outcomes and initial experience in a tertiary center

Medtronic's Hugo™ robotic surgery system for robot-assisted radical prostatectomy: a systematic review of current worldwide experiences

First Worldwide Report of a Total Colectomy with the Hugo RAS Platform

A multi-docking strategy for robotic LAR and deep pelvic surgery with the Hugo RAS system: experience from a tertiary referral center

First worldwide report on rectal resections with HugoTM surgical system: description of docking angles and tips for an effective setup

Implementation and outcomes in benign gynecological surgery with HUGO™ RAS system 12 months initial experience

Full robotic cholecystectomy: first worldwide experiences with HUGO RAS surgical platform

Robot-Assisted Radical Prostatectomy Performed with the Novel Surgical Robotic Platform HugoTM RAS: Monocentric First Series of 132 Cases Reporting Surgical, and Early Functional and Oncological Outcomes at a Tertiary Referral Robotic Center

Clash of the Titans: the first multi-center retrospective comparative study between da Vinci and HugoTM RAS surgical systems for the treatment of deep endometriosis

A Systematic Review and Pooled Analysis of Surgical, Oncological, and Functional Outcomes

1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes

The new robotic system HUGO RAS for gynecologic surgery: First European experience from Gemelli Hospital

Evaluating the Impact of Robotic IPAA

Outcomes of Robot-Assisted Surgery in Rectal Cancer Compared with Open and Laparoscopic Surgery

Robotic hernia repair with the novel HUGO robot system – An initial experience from a tertiary centre